Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer

Published: Nov. 14, 2023, 3:59 p.m.

Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11 - 15, 2023. Dr. Takahashi reported an improvement in median overall survival among patients with relapsed small cell lung cancer who had the ATR inhibitor berzosertib added to standard topotecan.